Evidence map›Paper›PMID 42257470›Full record

ArticleProceedings (Baylor University. Medical Center)2026

Comparative efficacy of ustekinumab and vedolizumab in anti-TNF-naive and anti-TNF-exposed patients with Crohn's disease: a matched cohort study.

Mohamed H Eldesouki, Khaled Elfert, Ahmed Ibrahim, Eslam M Rabea, Muhammad M Elsharkawy, Mohamed A Aldemerdash, George Obeng, Kanwarpreet Tandon, Jennifer Hadam-Veverka

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings (Baylor University. Medical Center), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mohamed H EldesoukiDepartment of Internal Medicine, New York Medical College at Saint Michael's Medical Center, Newark, New Jersey, USA.ORCID 0009-0009-6662-5883
Khaled ElfertDivision of Gastroenterology, West Virginia University School of Medicine, Morgantown, West Virginia, USA.
Ahmed IbrahimDivision of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston, South Carolina, USA.
Eslam M RabeaAlexandria Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Muhammad M ElsharkawyAlexandria Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Mohamed A AldemerdashFaculty of Medicine, Sohag University, Sohag, Egypt.
George ObengDivision of Gastroenterology, West Virginia University School of Medicine, Morgantown, West Virginia, USA.
Kanwarpreet TandonDivision of Gastroenterology, West Virginia University School of Medicine, Morgantown, West Virginia, USA.
Jennifer Hadam-VeverkaDivision of Gastroenterology, West Virginia University School of Medicine, Morgantown, West Virginia, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUstekinumab and vedolizumab are used in patients with Crohn's disease (CD). However, comparative studies evaluating their long-term efficacy in anti-TNF-naïve and anti-TNF-exposed populations remain limited.

methodsA retrospective cohort study utilizing the TriNetX US Collaborative Network database was conducted to compare the real-world efficacy of ustekinumab and vedolizumab in adult patients with CD. Patients were stratified into anti-TNF-naïve and anti-TNF-exposed cohorts, and 1:1 propensity score matching was employed. The primary outcome was rate of corticosteroid use at 12 and 24 months. Secondary outcomes included all-cause hospitalization rates and emergency department visits.

resultsIn the anti-TNF-naïve cohort (n = 2800 per group after matching), ustekinumab was associated with significantly lower steroid use at 12 months (29.8% vs 39.0%; adjusted hazard ratio [aHR] 0.71, 95% confidence interval [CI] 0.65-0.78;

conclusionsUstekinumab use was associated with lower corticosteroid exposure and reduced healthcare utilization compared to vedolizumab in anti-TNF-naïve and anti-TNF-exposed CD patients.

Indexed as

Antibodies, Monoclonal, HumanizedCrohn DiseaseGastrointestinal AgentsUstekinumabAdrenal Cortex HormonesAdultCohort StudiesFemaleHospitalizationHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeTumor Necrosis Factor-alphaAdrenal Cortex HormonesAntibodies, Monoclonal, HumanizedGastrointestinal AgentsTumor Necrosis Factor-alphaUstekinumabvedolizumabAnti-integrin therapyCrohn’s diseaseinflammatory bowel diseaseinterleukin-12/23 inhibitorustekinumabvedolizumab

Identifiers

PMID42257470
PMCPMC13524001

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.